OM1 has rolled out its new artificial intelligence-driven platform to provide personalised information on diagnosis, treatment, risk, use and clinical trials.
Dubbed PhenOM, the platform has been calibrated using OM1’s longitudinal health history database that includes data from over 300 million patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PhenOM leverages AI to recognise specific digital phenotypes related to conditions and outcomes, as well as comparing patients’ records to them for highlighting risks and options.
It is capable of offering customised healthcare inputs across the entire healthcare ecosystem, including life science research and point-of-care clinical decision making.
In addition, PhenOM collects details from a huge set of patients’ data, including unstructured clinical notes and disease activity metrics, to separate unique patterns of patients.
The platform synthesises these patterns into specific digital phenotypes or ‘fingerprints’.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese phenotypes can be assessed to help research and be deployed in real-world datasets, both inside and outside of OM1, along with health systems and via other patient-facing web portals.
OM1 AI and Personalised Medicine managing director Dr Joseph Zabinski said: “Most people have now heard of the promise of AI through GPT-4, but we still have not seen many really mature, real-world clinical applications using advanced language models.
“PhenOM is groundbreaking technology because it uses AI to translate actionable insights from our highly enriched datasets and phenotyping technology into opportunities for more personalised healthcare.
“This capability creates a huge potential for impact for all stakeholders, from identifying patients with under-diagnosed conditions to enabling personalised assessments of benefit for particular therapies and accelerating clinical trial enrolment.”
